Tumor News and Research

RSS

DFINE closes $25 million round of equity financing

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.

9 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Older women do not benefit from improvements in breast cancer treatments

The survival rates for older women with breast cancer lag behind younger women diagnosed with the disease, indicating that the elder population may be missing out on improvements in treatment and detection, according to new research from the University of Texas MD Anderson Cancer Center.

8 Nov 2011

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

In dozens of experiments in mice and in human cancer cells, a team of Johns Hopkins scientists has closely tied production of a cancer-causing protein called TWIST to the development of estrogen resistance in women with breast cancer.

8 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

NanoString closes $20M Series D round of equity financing

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it has closed $20 million in a Series D round of equity financing.

From NanoString Technologies 7 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

Karolinska Institute researchers discover novel cancer drug target

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target.

7 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011

Researchers discover two effective cancer killers

Researchers at the University of Southern California have identified two molecules that may be more effective cancer killers than are currently available on the market.

7 Nov 2011

Biologics reduce fatigue in people with RA

Treatment with a biologic agent reduces fatigue in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Link between use of anti-TNF therapy and malignant melanoma in RA patients

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis have a higher risk of developing malignant melanoma.

7 Nov 2011

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

As guidelines recommend, doctors appear to be stopping anti-TNF medications before surgery, but may be doing so far sooner than is necessary, according to a new study by researchers at Hospital for Special Surgery. These medications are used to treat a variety of inflammatory diseases, including rheumatoid arthritis, and better timing of withdrawal prior to surgery might minimize the risk of disease flares.

6 Nov 2011

SJH&MC the first in Southeast Michigan to offer Hyperthermic Intraperitoneal Chemotherapy

A unique treatment involving the use of hot chemotherapy is being offered at St. John Hospital and Medical Center. SJH&MC is the first hospital in Southeast Michigan and one of only approximately 20 centers nationwide to offer the treatment.

5 Nov 2011

Chemotherapy plus radiation improves overall survival for patients with stage II NPC

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

5 Nov 2011

Common gut pathogen increases activity of SMO gene and causes colon tumors

Working with lab cultures and mice, Johns Hopkins scientists have found that a strain of the common gut pathogen Bacteroides fragilis causes colon inflammation and increases activity of a gene called spermine oxidase (SMO) in the intestine.

5 Nov 2011

Quanticel, Celgene and Versant enter collaboration to discover and develop first-in-class cancer drugs

Privately held biotechnology company Quanticel Pharmaceuticals Inc. and Celgene Corporation, together with Versant Ventures, today announced they have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs.

4 Nov 2011